Use of glucose, insulin, and C-reactive protein to determine need for glucose tolerance testing (Q44548940)

4 December 2017

Use of glucose, insulin, and C-reactive protein to determine need for glucose tolerance testing (English)

1 reference

4 December 2017

Warren G Thompson

1

1 reference

4 December 2017

Erik J Bergstralh

series ordinal

2

1 reference

4 December 2017

Jeffrey M Slezak

series ordinal

3

1 reference

4 December 2017

language of work or name

1 reference

1 August 2003

1 reference

4 December 2017

1 reference

4 December 2017

11

1 reference

4 December 2017

1027-1032

1 reference

4 December 2017

8

1 reference

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

4 December 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Tests of glycemia for the diagnosis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Comparison of ADA and WHO screening methods for diabetes mellitus in obese patients. American Diabetes Association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Diagnosis of diabetes mellitus and intermediate glucose abnormalities in obese patients based on ADA (1997) and WHO (1985) criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Gender differences in C-reactive protein concentrations-confirmation with two sensitive methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Should we consider performing oral glucose tolerance tests more frequently in postmenopausal women for optimal screening of impaired glucose tolerance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Body mass index, diabetes, and C-reactive protein among U.S. adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Point: a glucose tolerance test is important for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Counterpoint: the oral glucose tolerance test is superfluous

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Predicting future cardiovascular disease: do we need the oral glucose tolerance test?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Impaired fasting glucose: how low should it go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Elevated C-reactive protein levels in overweight and obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2003.141

31 March 2020

Identifiers

DOI

10.1038/OBY.2003.141

1 reference

release_b3r7v6tvj5fsdjrzza5mzwvlxm

4 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b3r7v6tvj5fsdjrzza5mzwvlxm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference